GSK Signs a Synthetic Lethality Cancer Agreement with Ideaya for ~$170M

 GSK Signs a Synthetic Lethality Cancer Agreement with Ideaya for ~$170M

Fulcrum Therapeutics Signs an Exclusive Worldwide License Agreement with GSK to Develop and Commercialize Losmapimod for Facioscapulohumeral Muscular Dystrophy


  • Ideaya to receive ~$100M as upfront in cash, $20M as equity investment, $50M in cash as option exercise fee for the MAT2A program and is eligible to receive preclinical, clinical, and commercial milestones
  • The collaboration includes Ideaya’s synthetic lethality programs MAT2A, Pol Theta, and Werner Helicase programs, which are projected to reach clinical trials within the next 3yrs. Ideaya will lead the MAT2A program through early clinical development and is responsible for all costs of the MAT2A program prior to the GSK option exercise after that Ideaya is responsible for 20% of global development costs
  • Ideaya will get equal profit share in the US and ex-US royalties for the MAT2A and Werner Helicase programs, global royalties for Pol Theta. GSK will cover all research, development, and commercialization costs and will be responsible for all commercialization activities and costs globally for licensed products

Click here to read full press release/ article | Ref: GSK | Image: Pharmaworld

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on

Related post